Merck's Keytruda 'significantly improves survival compared to chemotherapy' in lung cancer patients

21 December 2015

Merck & Co’s (NYSE: MRK) immunotherapy drug Keytruda (pembrolizumab) ‘significantly improves survival compared to chemotherapy, a study has shown.

The results of the pivotal KEYNOTE-010 Phase II/III study were published in The Lancet and presented at the European Society for Medical Oncology (ESMO) Asia this week.

In the trial, 1,034 patients with advanced PD-L 1-positive non-small-cell lung cancer (NSCLC) were randomized to treatment with Keytruda (2mg/kg every three weeks) and Keytruda (10mg/kg every three weeks). Both groups were compared to patients who received docetaxel.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK